CircFOXK2 promotes hepatocellular carcinoma progression and leads to a poor clinical prognosis via regulating the Warburg effect

The Warburg effect is well-established to be essential for tumor progression and accounts for the poor clinical outcomes of hepatocellular carcinoma (HCC) patients. An increasing body of literature suggests that circular RNAs (circRNAs) are important regulators for HCC. However, few circRNAs involve...

Full description

Saved in:
Bibliographic Details
Published inJournal of experimental & clinical cancer research Vol. 42; no. 1; pp. 63 - 22
Main Authors Zheng, Jun, Yan, Xijing, Lu, Tongyu, Song, Wen, Li, Yang, Liang, Jinliang, Zhang, Jiebin, Cai, Jianye, Sui, Xin, Xiao, Jiaqi, Chen, Haitian, Chen, Guihua, Zhang, Qi, Liu, Yubin, Yang, Yang, Zheng, Kanghong, Pan, Zihao
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 15.03.2023
BioMed Central
BMC
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The Warburg effect is well-established to be essential for tumor progression and accounts for the poor clinical outcomes of hepatocellular carcinoma (HCC) patients. An increasing body of literature suggests that circular RNAs (circRNAs) are important regulators for HCC. However, few circRNAs involved in the Warburg effect of HCC have hitherto been investigated. Herein, we aimed to explore the contribution of circFOXK2 to glucose metabolism reprogramming in HCC. In the present study, different primers were designed to identify 14 circRNAs originating from the FOXK2 gene, and their differential expression between HCC and adjacent liver tissues was screened. Ultimately, circFOXK2 (hsa_circ_0000817) was selected for further research. Next, the clinical significance of circFOXK2 was evaluated. We then assessed the pro-oncogenic activity of circFOXK2 and its impact on the Warburg effect in both HCC cell lines and animal xenografts. Finally, the molecular mechanisms of how circFOXK2 regulates the Warburg effect of HCC were explored. CircFOXK2 was aberrantly upregulated in HCC tissues and positively correlated with poor clinical outcomes in patients that underwent radical hepatectomy. Silencing of circFOXK2 significantly suppressed HCC progression both in vitro and in vivo. Mechanistically, circFOXK2 upregulated the expression of protein FOXK2-142aa to promote LDHA phosphorylation and led to mitochondrial fission by regulating the miR-484/Fis1 pathway, ultimately activating the Warburg effect in HCC. CircFOXK2 is a prognostic biomarker of HCC that promotes the Warburg effect by promoting the expression of proteins and miRNA sponges that lead to tumor progression. Overall, circFOXK2 has huge prospects as a potential therapeutic target for patients with HCC.
AbstractList The Warburg effect is well-established to be essential for tumor progression and accounts for the poor clinical outcomes of hepatocellular carcinoma (HCC) patients. An increasing body of literature suggests that circular RNAs (circRNAs) are important regulators for HCC. However, few circRNAs involved in the Warburg effect of HCC have hitherto been investigated. Herein, we aimed to explore the contribution of circFOXK2 to glucose metabolism reprogramming in HCC. In the present study, different primers were designed to identify 14 circRNAs originating from the FOXK2 gene, and their differential expression between HCC and adjacent liver tissues was screened. Ultimately, circFOXK2 (hsa_circ_0000817) was selected for further research. Next, the clinical significance of circFOXK2 was evaluated. We then assessed the pro-oncogenic activity of circFOXK2 and its impact on the Warburg effect in both HCC cell lines and animal xenografts. Finally, the molecular mechanisms of how circFOXK2 regulates the Warburg effect of HCC were explored. CircFOXK2 was aberrantly upregulated in HCC tissues and positively correlated with poor clinical outcomes in patients that underwent radical hepatectomy. Silencing of circFOXK2 significantly suppressed HCC progression both in vitro and in vivo. Mechanistically, circFOXK2 upregulated the expression of protein FOXK2-142aa to promote LDHA phosphorylation and led to mitochondrial fission by regulating the miR-484/Fis1 pathway, ultimately activating the Warburg effect in HCC. CircFOXK2 is a prognostic biomarker of HCC that promotes the Warburg effect by promoting the expression of proteins and miRNA sponges that lead to tumor progression. Overall, circFOXK2 has huge prospects as a potential therapeutic target for patients with HCC.
BackgroundThe Warburg effect is well-established to be essential for tumor progression and accounts for the poor clinical outcomes of hepatocellular carcinoma (HCC) patients. An increasing body of literature suggests that circular RNAs (circRNAs) are important regulators for HCC. However, few circRNAs involved in the Warburg effect of HCC have hitherto been investigated. Herein, we aimed to explore the contribution of circFOXK2 to glucose metabolism reprogramming in HCC.MethodsIn the present study, different primers were designed to identify 14 circRNAs originating from the FOXK2 gene, and their differential expression between HCC and adjacent liver tissues was screened. Ultimately, circFOXK2 (hsa_circ_0000817) was selected for further research. Next, the clinical significance of circFOXK2 was evaluated. We then assessed the pro-oncogenic activity of circFOXK2 and its impact on the Warburg effect in both HCC cell lines and animal xenografts. Finally, the molecular mechanisms of how circFOXK2 regulates the Warburg effect of HCC were explored.ResultsCircFOXK2 was aberrantly upregulated in HCC tissues and positively correlated with poor clinical outcomes in patients that underwent radical hepatectomy. Silencing of circFOXK2 significantly suppressed HCC progression both in vitro and in vivo. Mechanistically, circFOXK2 upregulated the expression of protein FOXK2-142aa to promote LDHA phosphorylation and led to mitochondrial fission by regulating the miR-484/Fis1 pathway, ultimately activating the Warburg effect in HCC.ConclusionsCircFOXK2 is a prognostic biomarker of HCC that promotes the Warburg effect by promoting the expression of proteins and miRNA sponges that lead to tumor progression. Overall, circFOXK2 has huge prospects as a potential therapeutic target for patients with HCC.
Abstract Background The Warburg effect is well-established to be essential for tumor progression and accounts for the poor clinical outcomes of hepatocellular carcinoma (HCC) patients. An increasing body of literature suggests that circular RNAs (circRNAs) are important regulators for HCC. However, few circRNAs involved in the Warburg effect of HCC have hitherto been investigated. Herein, we aimed to explore the contribution of circFOXK2 to glucose metabolism reprogramming in HCC. Methods In the present study, different primers were designed to identify 14 circRNAs originating from the FOXK2 gene, and their differential expression between HCC and adjacent liver tissues was screened. Ultimately, circFOXK2 (hsa_circ_0000817) was selected for further research. Next, the clinical significance of circFOXK2 was evaluated. We then assessed the pro-oncogenic activity of circFOXK2 and its impact on the Warburg effect in both HCC cell lines and animal xenografts. Finally, the molecular mechanisms of how circFOXK2 regulates the Warburg effect of HCC were explored. Results CircFOXK2 was aberrantly upregulated in HCC tissues and positively correlated with poor clinical outcomes in patients that underwent radical hepatectomy. Silencing of circFOXK2 significantly suppressed HCC progression both in vitro and in vivo. Mechanistically, circFOXK2 upregulated the expression of protein FOXK2-142aa to promote LDHA phosphorylation and led to mitochondrial fission by regulating the miR-484/Fis1 pathway, ultimately activating the Warburg effect in HCC. Conclusions CircFOXK2 is a prognostic biomarker of HCC that promotes the Warburg effect by promoting the expression of proteins and miRNA sponges that lead to tumor progression. Overall, circFOXK2 has huge prospects as a potential therapeutic target for patients with HCC.
Background The Warburg effect is well-established to be essential for tumor progression and accounts for the poor clinical outcomes of hepatocellular carcinoma (HCC) patients. An increasing body of literature suggests that circular RNAs (circRNAs) are important regulators for HCC. However, few circRNAs involved in the Warburg effect of HCC have hitherto been investigated. Herein, we aimed to explore the contribution of circFOXK2 to glucose metabolism reprogramming in HCC. Methods In the present study, different primers were designed to identify 14 circRNAs originating from the FOXK2 gene, and their differential expression between HCC and adjacent liver tissues was screened. Ultimately, circFOXK2 (hsa_circ_0000817) was selected for further research. Next, the clinical significance of circFOXK2 was evaluated. We then assessed the pro-oncogenic activity of circFOXK2 and its impact on the Warburg effect in both HCC cell lines and animal xenografts. Finally, the molecular mechanisms of how circFOXK2 regulates the Warburg effect of HCC were explored. Results CircFOXK2 was aberrantly upregulated in HCC tissues and positively correlated with poor clinical outcomes in patients that underwent radical hepatectomy. Silencing of circFOXK2 significantly suppressed HCC progression both in vitro and in vivo. Mechanistically, circFOXK2 upregulated the expression of protein FOXK2-142aa to promote LDHA phosphorylation and led to mitochondrial fission by regulating the miR-484/Fis1 pathway, ultimately activating the Warburg effect in HCC. Conclusions CircFOXK2 is a prognostic biomarker of HCC that promotes the Warburg effect by promoting the expression of proteins and miRNA sponges that lead to tumor progression. Overall, circFOXK2 has huge prospects as a potential therapeutic target for patients with HCC. Keywords: Circular RNA, Hepatocellular carcinoma, The Warburg effect, Encoding capacity, miRNA sponge
The Warburg effect is well-established to be essential for tumor progression and accounts for the poor clinical outcomes of hepatocellular carcinoma (HCC) patients. An increasing body of literature suggests that circular RNAs (circRNAs) are important regulators for HCC. However, few circRNAs involved in the Warburg effect of HCC have hitherto been investigated. Herein, we aimed to explore the contribution of circFOXK2 to glucose metabolism reprogramming in HCC. In the present study, different primers were designed to identify 14 circRNAs originating from the FOXK2 gene, and their differential expression between HCC and adjacent liver tissues was screened. Ultimately, circFOXK2 (hsa_circ_0000817) was selected for further research. Next, the clinical significance of circFOXK2 was evaluated. We then assessed the pro-oncogenic activity of circFOXK2 and its impact on the Warburg effect in both HCC cell lines and animal xenografts. Finally, the molecular mechanisms of how circFOXK2 regulates the Warburg effect of HCC were explored. CircFOXK2 was aberrantly upregulated in HCC tissues and positively correlated with poor clinical outcomes in patients that underwent radical hepatectomy. Silencing of circFOXK2 significantly suppressed HCC progression both in vitro and in vivo. Mechanistically, circFOXK2 upregulated the expression of protein FOXK2-142aa to promote LDHA phosphorylation and led to mitochondrial fission by regulating the miR-484/Fis1 pathway, ultimately activating the Warburg effect in HCC. CircFOXK2 is a prognostic biomarker of HCC that promotes the Warburg effect by promoting the expression of proteins and miRNA sponges that lead to tumor progression. Overall, circFOXK2 has huge prospects as a potential therapeutic target for patients with HCC.
The Warburg effect is well-established to be essential for tumor progression and accounts for the poor clinical outcomes of hepatocellular carcinoma (HCC) patients. An increasing body of literature suggests that circular RNAs (circRNAs) are important regulators for HCC. However, few circRNAs involved in the Warburg effect of HCC have hitherto been investigated. Herein, we aimed to explore the contribution of circFOXK2 to glucose metabolism reprogramming in HCC.BACKGROUNDThe Warburg effect is well-established to be essential for tumor progression and accounts for the poor clinical outcomes of hepatocellular carcinoma (HCC) patients. An increasing body of literature suggests that circular RNAs (circRNAs) are important regulators for HCC. However, few circRNAs involved in the Warburg effect of HCC have hitherto been investigated. Herein, we aimed to explore the contribution of circFOXK2 to glucose metabolism reprogramming in HCC.In the present study, different primers were designed to identify 14 circRNAs originating from the FOXK2 gene, and their differential expression between HCC and adjacent liver tissues was screened. Ultimately, circFOXK2 (hsa_circ_0000817) was selected for further research. Next, the clinical significance of circFOXK2 was evaluated. We then assessed the pro-oncogenic activity of circFOXK2 and its impact on the Warburg effect in both HCC cell lines and animal xenografts. Finally, the molecular mechanisms of how circFOXK2 regulates the Warburg effect of HCC were explored.METHODSIn the present study, different primers were designed to identify 14 circRNAs originating from the FOXK2 gene, and their differential expression between HCC and adjacent liver tissues was screened. Ultimately, circFOXK2 (hsa_circ_0000817) was selected for further research. Next, the clinical significance of circFOXK2 was evaluated. We then assessed the pro-oncogenic activity of circFOXK2 and its impact on the Warburg effect in both HCC cell lines and animal xenografts. Finally, the molecular mechanisms of how circFOXK2 regulates the Warburg effect of HCC were explored.CircFOXK2 was aberrantly upregulated in HCC tissues and positively correlated with poor clinical outcomes in patients that underwent radical hepatectomy. Silencing of circFOXK2 significantly suppressed HCC progression both in vitro and in vivo. Mechanistically, circFOXK2 upregulated the expression of protein FOXK2-142aa to promote LDHA phosphorylation and led to mitochondrial fission by regulating the miR-484/Fis1 pathway, ultimately activating the Warburg effect in HCC.RESULTSCircFOXK2 was aberrantly upregulated in HCC tissues and positively correlated with poor clinical outcomes in patients that underwent radical hepatectomy. Silencing of circFOXK2 significantly suppressed HCC progression both in vitro and in vivo. Mechanistically, circFOXK2 upregulated the expression of protein FOXK2-142aa to promote LDHA phosphorylation and led to mitochondrial fission by regulating the miR-484/Fis1 pathway, ultimately activating the Warburg effect in HCC.CircFOXK2 is a prognostic biomarker of HCC that promotes the Warburg effect by promoting the expression of proteins and miRNA sponges that lead to tumor progression. Overall, circFOXK2 has huge prospects as a potential therapeutic target for patients with HCC.CONCLUSIONSCircFOXK2 is a prognostic biomarker of HCC that promotes the Warburg effect by promoting the expression of proteins and miRNA sponges that lead to tumor progression. Overall, circFOXK2 has huge prospects as a potential therapeutic target for patients with HCC.
ArticleNumber 63
Audience Academic
Author Cai, Jianye
Sui, Xin
Zhang, Qi
Pan, Zihao
Zheng, Kanghong
Song, Wen
Liu, Yubin
Yang, Yang
Zhang, Jiebin
Chen, Guihua
Xiao, Jiaqi
Lu, Tongyu
Li, Yang
Liang, Jinliang
Chen, Haitian
Zheng, Jun
Yan, Xijing
Author_xml – sequence: 1
  givenname: Jun
  surname: Zheng
  fullname: Zheng, Jun
– sequence: 2
  givenname: Xijing
  surname: Yan
  fullname: Yan, Xijing
– sequence: 3
  givenname: Tongyu
  surname: Lu
  fullname: Lu, Tongyu
– sequence: 4
  givenname: Wen
  surname: Song
  fullname: Song, Wen
– sequence: 5
  givenname: Yang
  surname: Li
  fullname: Li, Yang
– sequence: 6
  givenname: Jinliang
  surname: Liang
  fullname: Liang, Jinliang
– sequence: 7
  givenname: Jiebin
  surname: Zhang
  fullname: Zhang, Jiebin
– sequence: 8
  givenname: Jianye
  surname: Cai
  fullname: Cai, Jianye
– sequence: 9
  givenname: Xin
  surname: Sui
  fullname: Sui, Xin
– sequence: 10
  givenname: Jiaqi
  surname: Xiao
  fullname: Xiao, Jiaqi
– sequence: 11
  givenname: Haitian
  surname: Chen
  fullname: Chen, Haitian
– sequence: 12
  givenname: Guihua
  surname: Chen
  fullname: Chen, Guihua
– sequence: 13
  givenname: Qi
  surname: Zhang
  fullname: Zhang, Qi
– sequence: 14
  givenname: Yubin
  surname: Liu
  fullname: Liu, Yubin
– sequence: 15
  givenname: Yang
  surname: Yang
  fullname: Yang, Yang
– sequence: 16
  givenname: Kanghong
  surname: Zheng
  fullname: Zheng, Kanghong
– sequence: 17
  givenname: Zihao
  surname: Pan
  fullname: Pan, Zihao
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36922872$$D View this record in MEDLINE/PubMed
BookMark eNp9kk-P1CAYhxuzxv2jX8CDITExXroCBUpPZjNxdeMme9HojVAKHTYURqCbePOjS2fWdWZjDGmg8LwP7ZvfaXXkg9dV9RLBc4Q4e5dQAwmrIW7KwzCp0ZPqBLWU1V3H2NHe-rg6TekWQoY61D2rjhvWYcxbfFL9WtmoLm--f8ZgE8MUsk5grTcyB6Wdm52MQMmorA-TXIgx6pRs8ED6ATgthwRyAOUohEI6662Sbgv6kGwCd1aCqMciytaPIK81-CZjP8cRaGO0ys-rp0a6pF_cz2fV18sPX1af6uubj1eri-ta0Y7muumJMlTTXslW9Vg2yjBjGMVIDprppqgMoaynLTc9QgZxhbUZCO0HBIeBNmfV1c47BHkrNtFOMv4UQVqx3QhxFDJmq5wWmCHaG8YaDQ3hEHUdgZzA7bukHBXX-51rM_eTHpT2OUp3ID088XYtxnAnEISId4gVw9t7Qww_Zp2ymGxaOi69DnMSuOW87SjmpKCvH6G3YY6-9GpLEU4Jav5Soyx_YL0J5WK1SMVFSxBpEWWL6_wfVBmDnqwq6TK27B8UvNkrWGvp8joFN-cSgXQIvtpvyUMv_iStAHgHqBhSito8IAiKJc5iF2dR4iy2cRZLo_mjImWzXC4v323d_0p_A_zT-Z8
CitedBy_id crossref_primary_10_1007_s10142_023_01096_y
crossref_primary_10_1016_j_redox_2025_103556
crossref_primary_10_1038_s41420_024_02261_3
crossref_primary_10_1186_s13045_023_01452_2
crossref_primary_10_1186_s12935_023_03186_0
crossref_primary_10_1186_s12943_024_02101_z
crossref_primary_10_1016_j_drup_2024_101097
crossref_primary_10_3390_biomedicines13010160
crossref_primary_10_3748_wjg_v31_i11_102848
crossref_primary_10_1038_s12276_025_01413_4
crossref_primary_10_1002_mco2_70055
crossref_primary_10_1016_j_cellsig_2024_111243
crossref_primary_10_1016_j_gendis_2024_101347
crossref_primary_10_1016_j_bcp_2024_116419
crossref_primary_10_3892_ijo_2024_5637
crossref_primary_10_1021_cbmi_4c00105
Cites_doi 10.1016/j.jhep.2018.01.012
10.1002/path.4525
10.1016/j.biocel.2017.05.019
10.1038/s41586-019-0900-5
10.1016/j.cell.2018.12.021
10.1038/nbt.2890
10.1186/s12943-020-1147-3
10.1038/s41576-019-0158-7
10.1186/s12943-020-01179-5
10.1056/NEJMra1001683
10.7150/thno.33758
10.1002/hep.30795
10.1158/1078-0432.CCR-19-0674
10.1158/1078-0432.CCR-13-0304
10.1002/ijc.31278
10.1158/0008-5472.CAN-21-1259
10.1002/hep.30666
10.1002/advs.201900949
10.1126/science.1160809
10.3322/caac.21492
10.1186/s12943-018-0909-7
10.1002/hep.30671
10.1016/j.cell.2011.07.014
10.1080/15476286.2015.1020271
10.1186/s12943-019-1129-5
10.1016/j.cell.2016.07.035
10.1038/onc.2017.6
10.1186/s12943-019-1046-7
10.1038/ncomms15308
10.1038/emboj.2013.53
10.1158/0008-5472.CAN-19-3268
10.1038/s41419-020-2424-1
10.1186/s12943-020-1135-7
10.7150/thno.31716
10.1186/s12943-019-1086-z
10.1016/j.ccell.2016.09.010
10.1002/hep.31068
10.1002/hep.29462
10.1002/hep.30793
10.1186/s12943-019-1031-1
10.2147/OTT.S157126
10.1016/j.molcel.2014.08.019
10.1016/S0140-6736(03)14964-1
10.1038/nature11928
10.1186/s12935-017-0407-9
10.1002/1878-0261.12424
10.1016/j.cmet.2018.10.011
10.1016/j.ymthe.2021.08.027
10.1016/j.canlet.2019.10.029
ContentType Journal Article
Copyright 2023. The Author(s).
COPYRIGHT 2023 BioMed Central Ltd.
2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2023
Copyright_xml – notice: 2023. The Author(s).
– notice: COPYRIGHT 2023 BioMed Central Ltd.
– notice: 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2023
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s13046-023-02624-1
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni)
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE
Publicly Available Content Database




MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central Database Suite (ProQuest)
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1756-9966
EndPage 22
ExternalDocumentID oai_doaj_org_article_2615bf663e0f4801994084063e0fa581
PMC10018916
A741471564
36922872
10_1186_s13046_023_02624_1
Genre Journal Article
GeographicLocations Massachusetts
China
Germany
United States--US
GeographicLocations_xml – name: China
– name: Massachusetts
– name: Germany
– name: United States--US
GrantInformation_xml – fundername: Natural Science Foundation of China
  grantid: 81901943
– fundername: Guangdong Basic and Applied Basic Research Foundation
  grantid: 2021A1515111058
– fundername: Natural Science Foundation of Guangdong Province
  grantid: 2021A1515012136
– fundername: National Natural Science Foundation of China
  grantid: 82170631
– fundername: Natural Science Foundation of Guangdong Province
  grantid: 2021A1515010571
– fundername: National Natural Science Foundation of China
  grantid: 82073171
– fundername: Guangdong Key Laboratory of Liver Disease Research
  grantid: 2020B1212060019
– fundername: Natural Science Foundation of Guangdong Province
  grantid: 2021A1515011156
– fundername: National 13th Five-Year Science and Technology Plan Major Projects of China
  grantid: 2017ZX10203205
– fundername: National key research and development program
  grantid: 2017YFA0104304
– fundername: ;
  grantid: 202102020237
– fundername: ;
– fundername: ;
  grantid: 201803040005
– fundername: ;
  grantid: 2019A1515011698; 2021A1515012136; 2021A1515011156; 2021A1515010571
– fundername: ;
  grantid: 2020B1212060019
– fundername: ;
  grantid: WW201905
– fundername: ;
  grantid: 82073171; 81900597; 81802897; 81770648; 81970567; 82100693; 82170631; 81972286
– fundername: ;
  grantid: P02093; P02095
– fundername: ;
  grantid: WW201701
– fundername: ;
  grantid: 2021A1515111058
GroupedDBID ---
0R~
29K
2WC
4.4
5GY
5VS
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ADBBV
ADRAZ
ADUKV
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AOIJS
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
D-I
DIK
DU5
E3Z
EBD
EBLON
EBS
ESX
F5P
FYUFA
GROUPED_DOAJ
HMCUK
HYE
IAO
IEA
IHR
IHW
INH
INR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
TR2
TUS
UKHRP
~8M
CGR
CUY
CVF
ECM
EIF
NPM
PMFND
3V.
7XB
8FK
AZQEC
DWQXO
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c595t-3b4cf5e5bca7cb2a3cf6ff6521ade6e3fecf456b578fb11f18c2efd45bd10dd53
IEDL.DBID 7X7
ISSN 1756-9966
0392-9078
IngestDate Wed Aug 27 01:21:23 EDT 2025
Thu Aug 21 18:37:30 EDT 2025
Fri Jul 11 03:48:17 EDT 2025
Fri Jul 25 06:11:25 EDT 2025
Tue Jun 17 21:18:43 EDT 2025
Tue Jun 10 20:42:41 EDT 2025
Thu May 22 21:19:42 EDT 2025
Thu Apr 03 07:01:42 EDT 2025
Tue Jul 01 02:26:49 EDT 2025
Thu Apr 24 22:57:24 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords The Warburg effect
miRNA sponge
Circular RNA
Hepatocellular carcinoma
Encoding capacity
Language English
License 2023. The Author(s).
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c595t-3b4cf5e5bca7cb2a3cf6ff6521ade6e3fecf456b578fb11f18c2efd45bd10dd53
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://www.proquest.com/docview/2788485413?pq-origsite=%requestingapplication%
PMID 36922872
PQID 2788485413
PQPubID 105475
PageCount 22
ParticipantIDs doaj_primary_oai_doaj_org_article_2615bf663e0f4801994084063e0fa581
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10018916
proquest_miscellaneous_2788795284
proquest_journals_2788485413
gale_infotracmisc_A741471564
gale_infotracacademiconefile_A741471564
gale_healthsolutions_A741471564
pubmed_primary_36922872
crossref_primary_10_1186_s13046_023_02624_1
crossref_citationtrail_10_1186_s13046_023_02624_1
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-03-15
PublicationDateYYYYMMDD 2023-03-15
PublicationDate_xml – month: 03
  year: 2023
  text: 2023-03-15
  day: 15
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Journal of experimental & clinical cancer research
PublicationTitleAlternate J Exp Clin Cancer Res
PublicationYear 2023
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References JN Vo (2624_CR5) 2019; 176
F Bray (2624_CR1) 2018; 68
Y Su (2624_CR25) 2020; 19
J Guarnerio (2624_CR7) 2016; 166
S Memczak (2624_CR9) 2013; 495
P Wu (2624_CR39) 2020; 19
J Li (2624_CR44) 2022; 82
L Jin (2624_CR31) 2017; 36
Y Wei (2624_CR16) 2020; 71
B Wang (2624_CR36) 2018; 11
H Wang (2624_CR14) 2018; 17
SM Sanderson (2624_CR21) 2018; 28
V Sukonina (2624_CR23) 2019; 566
L Salmena (2624_CR42) 2011; 146
Y Hu (2624_CR45) 2017; 17
F Du (2624_CR35) 2019; 9
J Yu (2624_CR17) 2018; 68
J Zheng (2624_CR28) 2020; 11
ZQ Hu (2624_CR12) 2020; 72
Z Pan (2624_CR10) 2020; 19
WM Linehan (2624_CR32) 2013; 19
YH Lin (2624_CR19) 2018; 67
L Wang (2624_CR15) 2019; 18
WR Jeck (2624_CR8) 2014; 32
LL Chen (2624_CR4) 2015; 12
Q Li (2624_CR13) 2019; 70
T Gao (2624_CR48) 2020; 469
C Hage (2624_CR26) 2019; 70
G Qin (2624_CR27) 2020; 71
F Zhang (2624_CR37) 2018; 142
JM Llovet (2624_CR2) 2003; 362
L Qiu (2624_CR34) 2019; 13
Y Ji (2624_CR40) 2017; 8
R Ashwal-Fluss (2624_CR6) 2014; 56
N Li (2624_CR47) 2020; 26
CH Wong (2624_CR38) 2020; 80
2624_CR29
PF Zhang (2624_CR18) 2019; 18
L Shan (2624_CR22) 2016; 30
MG Vander Heiden (2624_CR20) 2009; 324
M Lei (2624_CR30) 2020; 19
Q Mei (2624_CR46) 2015; 236
LS Kristensen (2624_CR33) 2019; 20
P Li (2624_CR43) 2022; 30
HB El-Serag (2624_CR3) 2011; 365
MF Lin (2624_CR24) 2017; 88
L Wei (2624_CR41) 2019; 18
L Chen (2624_CR11) 2020; 7
J Hagenbuchner (2624_CR49) 2019; 9
References_xml – volume: 68
  start-page: 1214
  issue: 6
  year: 2018
  ident: 2624_CR17
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2018.01.012
– volume: 236
  start-page: 165
  issue: 2
  year: 2015
  ident: 2624_CR46
  publication-title: J Pathol
  doi: 10.1002/path.4525
– volume: 88
  start-page: 155
  year: 2017
  ident: 2624_CR24
  publication-title: Int J Biochem Cell Biol
  doi: 10.1016/j.biocel.2017.05.019
– volume: 566
  start-page: 279
  issue: 7743
  year: 2019
  ident: 2624_CR23
  publication-title: Nature
  doi: 10.1038/s41586-019-0900-5
– volume: 176
  start-page: 869
  issue: 4
  year: 2019
  ident: 2624_CR5
  publication-title: Cell
  doi: 10.1016/j.cell.2018.12.021
– volume: 32
  start-page: 453
  issue: 5
  year: 2014
  ident: 2624_CR8
  publication-title: Nat Biotechnol
  doi: 10.1038/nbt.2890
– volume: 19
  start-page: 22
  issue: 1
  year: 2020
  ident: 2624_CR39
  publication-title: Mol Cancer
  doi: 10.1186/s12943-020-1147-3
– volume: 20
  start-page: 675
  issue: 11
  year: 2019
  ident: 2624_CR33
  publication-title: Nat Rev Genet
  doi: 10.1038/s41576-019-0158-7
– volume: 19
  start-page: 71
  issue: 1
  year: 2020
  ident: 2624_CR10
  publication-title: Mol Cancer
  doi: 10.1186/s12943-020-01179-5
– volume: 365
  start-page: 1118
  issue: 12
  year: 2011
  ident: 2624_CR3
  publication-title: N Engl J Med
  doi: 10.1056/NEJMra1001683
– volume: 9
  start-page: 4909
  issue: 17
  year: 2019
  ident: 2624_CR49
  publication-title: Theranostics
  doi: 10.7150/thno.33758
– volume: 71
  start-page: 130
  issue: 1
  year: 2020
  ident: 2624_CR16
  publication-title: Hepatology
  doi: 10.1002/hep.30795
– volume: 26
  start-page: 1736
  issue: 7
  year: 2020
  ident: 2624_CR47
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-19-0674
– volume: 19
  start-page: 3345
  issue: 13
  year: 2013
  ident: 2624_CR32
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-13-0304
– volume: 142
  start-page: 2543
  issue: 12
  year: 2018
  ident: 2624_CR37
  publication-title: Int J Cancer
  doi: 10.1002/ijc.31278
– volume: 82
  start-page: 1055
  issue: 6
  year: 2022
  ident: 2624_CR44
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-21-1259
– volume: 70
  start-page: 1280
  issue: 4
  year: 2019
  ident: 2624_CR26
  publication-title: Hepatology
  doi: 10.1002/hep.30666
– volume: 7
  start-page: 1900949
  issue: 4
  year: 2020
  ident: 2624_CR11
  publication-title: Adv Sci (Weinh)
  doi: 10.1002/advs.201900949
– volume: 324
  start-page: 1029
  issue: 5930
  year: 2009
  ident: 2624_CR20
  publication-title: Science
  doi: 10.1126/science.1160809
– volume: 68
  start-page: 394
  issue: 6
  year: 2018
  ident: 2624_CR1
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21492
– volume: 17
  start-page: 165
  issue: 1
  year: 2018
  ident: 2624_CR14
  publication-title: Mol Cancer
  doi: 10.1186/s12943-018-0909-7
– volume: 70
  start-page: 1298
  issue: 4
  year: 2019
  ident: 2624_CR13
  publication-title: Hepatology
  doi: 10.1002/hep.30671
– volume: 146
  start-page: 353
  issue: 3
  year: 2011
  ident: 2624_CR42
  publication-title: Cell
  doi: 10.1016/j.cell.2011.07.014
– volume: 12
  start-page: 381
  issue: 4
  year: 2015
  ident: 2624_CR4
  publication-title: RNA Biol
  doi: 10.1080/15476286.2015.1020271
– volume: 19
  start-page: 23
  issue: 1
  year: 2020
  ident: 2624_CR25
  publication-title: Mol Cancer
  doi: 10.1186/s12943-019-1129-5
– volume: 166
  start-page: 1055
  issue: 4
  year: 2016
  ident: 2624_CR7
  publication-title: Cell
  doi: 10.1016/j.cell.2016.07.035
– volume: 36
  start-page: 3797
  issue: 27
  year: 2017
  ident: 2624_CR31
  publication-title: Oncogene
  doi: 10.1038/onc.2017.6
– volume: 18
  start-page: 119
  issue: 1
  year: 2019
  ident: 2624_CR15
  publication-title: Mol Cancer
  doi: 10.1186/s12943-019-1046-7
– volume: 8
  start-page: 15308
  year: 2017
  ident: 2624_CR40
  publication-title: Nat Commun
  doi: 10.1038/ncomms15308
– ident: 2624_CR29
  doi: 10.1038/emboj.2013.53
– volume: 80
  start-page: 2138
  issue: 11
  year: 2020
  ident: 2624_CR38
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-19-3268
– volume: 11
  start-page: 256
  issue: 4
  year: 2020
  ident: 2624_CR28
  publication-title: Cell Death Dis
  doi: 10.1038/s41419-020-2424-1
– volume: 19
  start-page: 30
  issue: 1
  year: 2020
  ident: 2624_CR30
  publication-title: Mol Cancer
  doi: 10.1186/s12943-020-1135-7
– volume: 9
  start-page: 3879
  issue: 13
  year: 2019
  ident: 2624_CR35
  publication-title: Theranostics
  doi: 10.7150/thno.31716
– volume: 18
  start-page: 147
  issue: 1
  year: 2019
  ident: 2624_CR41
  publication-title: Mol Cancer
  doi: 10.1186/s12943-019-1086-z
– volume: 30
  start-page: 708
  issue: 5
  year: 2016
  ident: 2624_CR22
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2016.09.010
– volume: 72
  start-page: 906
  issue: 3
  year: 2020
  ident: 2624_CR12
  publication-title: Hepatology
  doi: 10.1002/hep.31068
– volume: 67
  start-page: 188
  issue: 1
  year: 2018
  ident: 2624_CR19
  publication-title: Hepatology
  doi: 10.1002/hep.29462
– volume: 71
  start-page: 112
  issue: 1
  year: 2020
  ident: 2624_CR27
  publication-title: Hepatology
  doi: 10.1002/hep.30793
– volume: 18
  start-page: 105
  issue: 1
  year: 2019
  ident: 2624_CR18
  publication-title: Mol Cancer
  doi: 10.1186/s12943-019-1031-1
– volume: 11
  start-page: 1067
  year: 2018
  ident: 2624_CR36
  publication-title: Onco Targets Ther
  doi: 10.2147/OTT.S157126
– volume: 56
  start-page: 55
  issue: 1
  year: 2014
  ident: 2624_CR6
  publication-title: Mol Cell
  doi: 10.1016/j.molcel.2014.08.019
– volume: 362
  start-page: 1907
  issue: 9399
  year: 2003
  ident: 2624_CR2
  publication-title: Lancet
  doi: 10.1016/S0140-6736(03)14964-1
– volume: 495
  start-page: 333
  issue: 7441
  year: 2013
  ident: 2624_CR9
  publication-title: Nature
  doi: 10.1038/nature11928
– volume: 17
  start-page: 36
  year: 2017
  ident: 2624_CR45
  publication-title: Cancer Cell Int
  doi: 10.1186/s12935-017-0407-9
– volume: 13
  start-page: 441
  issue: 2
  year: 2019
  ident: 2624_CR34
  publication-title: Mol Oncol
  doi: 10.1002/1878-0261.12424
– volume: 28
  start-page: 669
  issue: 5
  year: 2018
  ident: 2624_CR21
  publication-title: Cell Metab
  doi: 10.1016/j.cmet.2018.10.011
– volume: 30
  start-page: 431
  issue: 1
  year: 2022
  ident: 2624_CR43
  publication-title: Mol Ther
  doi: 10.1016/j.ymthe.2021.08.027
– volume: 469
  start-page: 89
  year: 2020
  ident: 2624_CR48
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2019.10.029
SSID ssj0061919
Score 2.445102
Snippet The Warburg effect is well-established to be essential for tumor progression and accounts for the poor clinical outcomes of hepatocellular carcinoma (HCC)...
Background The Warburg effect is well-established to be essential for tumor progression and accounts for the poor clinical outcomes of hepatocellular carcinoma...
BackgroundThe Warburg effect is well-established to be essential for tumor progression and accounts for the poor clinical outcomes of hepatocellular carcinoma...
Abstract Background The Warburg effect is well-established to be essential for tumor progression and accounts for the poor clinical outcomes of hepatocellular...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 63
SubjectTerms Animals
Apoptosis
Cancer therapies
Carcinoma, Hepatocellular - genetics
Carcinoma, Hepatocellular - pathology
Cell Line, Tumor
Cell Proliferation - genetics
Circular RNA
Dehydrogenases
Development and progression
Encoding capacity
Flow cytometry
Gene expression
Gene Expression Regulation, Neoplastic
Glucose metabolism
Hepatocellular carcinoma
Hepatoma
Humans
Hybridization
Kinases
Liver
Liver cancer
Liver Neoplasms - genetics
Liver Neoplasms - pathology
Medical prognosis
MicroRNAs
MicroRNAs - genetics
MicroRNAs - metabolism
miRNA sponge
Phosphorylation
Physiological aspects
Prognosis
Proteins
RNA
RNA, Circular - genetics
The Warburg effect
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gL4k2gFCMhcUBW147tjY9txaoCFS5U7M3yk65UkmqTcuanM7az0UZIcOGwh6zHUjIPf98k4zFCb4ER8EiNAeZmHOE2OmIldcQDmgMAgcfk2pyLz_L8kn9ci_XeUV-pJqy0By6KOwaGL2wEXAyLmFqdKMUXkJTkayPypmsGmLdLpsoaDFkBVbstMo087mn6AEgAn-AnGSd0BkO5W_-fa_IeKM0LJvcQaPUA3R-pIz4pt_wQ3QntI3T3Yvw4_hj9Otts3erL-hPDN7nILvT4CtBm6NLb-VRuil06Oajtfhic67JKTw5sWo-vwdY9HjoMQ10HkuOOySzYdv2mxz83Bm_L0fWAdxiYI_5mklG-41IV8gRdrj58PTsn4wELxAklBlJb7qIIwjqzdJaZ2kUZowRENz7IUMPUCATLQlRHS2mkjWMhei6spwvvRf0UHbRdG54j7E3k3jseFt5yEZVZAjNUMgTFozVcVIju9K3d2H08HYJxrXMW0khdbKTBRjrbSNMKvZ_m3JTeG3-VPk1mnCRT3-z8B3iTHr1J_8ubKvQ6OYEum1Cn6NcnQLwAxoXkFXqXJVL8wwM4M25jADWkTlozycOZJMStmw_vHE2P60av2bJpeCOAWVTozTScZqZauDZ0t0VmqQTwigo9K345PXQtFYMcmFWomXnsTCvzkXZzlbuKp2ZcDSQLL_6HHl-ieyxHW02oOEQHw_Y2vAL2NtijHKi_AVrKQQI
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELaqIiEuiDeBAkZC4oAM68R2kgNCpWJVgRYurNib5We70jYpSYrgxk9n7DzUiKqHPex6HCWemXzfrMczCL0CRsA8VQqYmzKEaW-IFtQQC2gOAAQWE3NzVl_F8Zp93vDNHhrbHQ0L2F4Z2oV-Uutm9_b3zz8fwOHfR4cvxLuWhu09AugDH5EyAtHQDUCmPDjqik27ChArxEYfgJiCBJ4_HqK58hozoIr1_P9_a1-CrXlK5SWMWt5BtwdyiQ97a7iL9lx1D91cDdvn99Hfo21jlt82X1J8HtPwXItPAY-6Ovx_HxJSsQm9har6TOGYudVX7cCqsngH1tDirsYwVNcgOZypjIJV3W5b_GurcNM3twdExMAt8Q8V1HaC-7yRB2i9_PT96JgMLRiI4SXvSKaZ8dxxbVRudKoy44X3AjBfWSdcBlM9UDANfu81pZ4WJnXeMq4tXVjLs4dov6or9xhhqzyz1jC3sJpxX6ocuGMpnCuZ14rxBNFxvaUZ6pOHNhk7GeOUQsheRxJ0JKOOJE3Qm2nOeV-d41rpj0GNk2SorB1_qJsTOTiqhIiSaw88zC18KK1TlmwBQXD8rngBF3kRjED2x1Sn94M8BGoGQM8FS9DrKBFsFh7AqOGgAyxDqLU1kzyYSYJnm_nwaGhydAyZ5kXBCg7cI0Evp-EwM2TLVa6-6GXykgPzSNCj3i6nh85EmUKUnCaomFnsbFXmI9X2NNYdD-W6Cggnnlx_X0_RrTT6UUYoP0D7XXPhngFz6_Tz6I7_ALdsP14
  priority: 102
  providerName: Scholars Portal
Title CircFOXK2 promotes hepatocellular carcinoma progression and leads to a poor clinical prognosis via regulating the Warburg effect
URI https://www.ncbi.nlm.nih.gov/pubmed/36922872
https://www.proquest.com/docview/2788485413
https://www.proquest.com/docview/2788795284
https://pubmed.ncbi.nlm.nih.gov/PMC10018916
https://doaj.org/article/2615bf663e0f4801994084063e0fa581
Volume 42
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9swEBdbC2MvY99z22UaDPYwRCNbUuyn0ZSGspFulJWFvQh9toHOzuJ0z_vTd5IVr2bQBxscnUysO93vTjrdIfQOLALmqVJguSlDmPaGaEENsYDmAEAgMTE2Z34mTi_YpwVfpAW3NoVVbnViVNS2MWGN_DAHX42VHHTux9UvEqpGhd3VVELjPtoNqctCSNdk0Ttc4BvEwh6AkIIEu357aKYUhy0NW4IEEAsukTNCB8AU8_f_r6VvwdQwhPIWJs0eo0fJmMRHHfefoHuufooezNN2-TP053i5NrMvi885XsWwO9fiK8CfTRPW60MAKjahllDd_FQ4Rmp1WTqwqi2-Bu63eNNgaGoaoExnKCNh3bTLFv9eKrzuitkDAmKwJfF3Fdh0ibs4kefoYnby7fiUpJILxPCKb0ihmfHccW3UxOhcFcYL7wVgvLJOuAK6ejC5NMxzryn1tDS585ZxbenYWl68QDt1U7tXCFvlmbWGubHVjPtKTcBWrIRzFfNaMZ4huh1vaVI-8lAW41pGv6QUsuORBB7JyCNJM_Sh77PqsnHcST0NbOwpQybt-EOzvpRpYkrwILn2YHe5sQ-pdKqKjcHpjc-Kl_CSN0EIZHcstdcH8ghMMQB2LliG3keKoBHgA4xKBxtgGEJurQHlwYASZrIZNm8FTSZN0sp_cp-ht31z6Bmi42rX3HQ0k4qDpZGhl51c9h9diCoHrzjPUDmQ2MGoDFvq5VXMMx7Sc5XgPuzd_b_20cM8zqOCUH6AdjbrG_caLLWNHsXpOEK705Ozr-ejuN4B9zkr4X4-_fEXSulAwg
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELemTgJeEN8EBjMSiAcUrU5sN3lAaBurOroWhDaxN-PPrtJIStOBeOMv4m_k7CRlEdLe9tCH1Jeo8Z1_97v6fIfQS2AE1BEpgblJHVPldKw40bEBbw4OCCwm5OZMpnx0Qj-cstMN9Kc9C-PTKltMDEBtSu3_I99JIFajGQPMfbf4HvuuUX53tW2hUZvF2P76CSFb9fbwPej3VZIMD473R3HTVSDWLGerOFVUO2aZ0nKgVSJT7bhzHNyYNJbb1FntgFUoMGWnCHEk04l1hjJlSN8Y3yUCIH-TphDK9NDm3sH00-cW-yEaCa1EwCfz2EcS7TGdjO9UxG9CxuAj4cMTGpOOKwwdA_73C5ccYzdp85IXHN5Btxv6indre7uLNmxxD92YNBv099Hv_flSDz-ejhO8CIl-tsJn4PFWpd8h8CmvWPvuRUX5TeKQG1bXBcGyMPgc7K3CqxLDUFmCZHNqMwgWZTWv8I-5xEs7Cz3HihkG9oq_SG8YM1xnpjxAJ9eijoeoV5SFfYywkY4ao6ntG0WZy-UA2GnOrc2pU5KyCJF2voVuKqD7RhznIkRCGRe1jgToSAQdCRKhN-t7FnX9jyul97wa15K-dnf4olzORAMFAmJWphwwPdt3vnhPntM-hNnhWrIMHrLtjUDUB2HXCCR2gfwBlWCcRuh1kPAYBC-gZXOUAqbBV_PqSG51JAE7dHe4NTTRYFcl_q20CL1YD_s7fT5eYcuLWmaQM-A2EXpU2-X6pVOeJxCHJxHKOhbbmZXuSDE_C5XNfUGwDAKWJ1f_rm10c3Q8ORJHh9PxU3QrCWsqjQnbQr3V8sI-A564Us-bxYnR1-vGg7_P8n4N
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=CircFOXK2+promotes+hepatocellular+carcinoma+progression+and+leads+to+a+poor+clinical+prognosis+via+regulating+the+Warburg+effect&rft.jtitle=Journal+of+experimental+%26+clinical+cancer+research&rft.au=Zheng%2C+Jun&rft.au=Xijing+Yan&rft.au=Lu%2C+Tongyu&rft.au=Song%2C+Wen&rft.date=2023-03-15&rft.pub=BioMed+Central&rft.issn=1756-9966&rft.volume=42&rft.spage=1&rft_id=info:doi/10.1186%2Fs13046-023-02624-1
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-9966&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-9966&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-9966&client=summon